Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07578571 | A Phase 1 Study of IM-1617 in Participants With Advanced Cancer | PHASE1 | RECRUITING | 175 | — | — | May 1, 2026 | Jan 1, 2029 | May 22, 2026 | 1 | United States |
Type, frequency, seriousness, and severity of adverse events (AEs) graded using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 6.0
Type, frequency, seriousness, and severity of adverse events (AEs) graded using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 6.0
Type, frequency, seriousness, and severity of adverse events (AEs) graded using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 6.0
Type, frequency, seriousness, and severity of adverse events (AEs) graded using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 6.0
| Arm | Type | Description |
|---|---|---|
| IM-1617 Dose Escalation | EXPERIMENTAL | IM-1617 given into the vein (IV; intravenously) |
| IM-1617 Monotherapy Dose Expansion | EXPERIMENTAL | IM-1617 given into the vein (IV; intravenously) |
| Name | Type | Description |
|---|---|---|
| IM-1617 | DRUG | IM-1617 is an antibody-drug conjugate |
Inclusion Criteria: 1. Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2 2. Part A: Histological diagnosis of one of the following unresectable locally advanced or metastatic solid tumors: * CRC, all subtypes * NSCLC: * Non-squamous cell carcinoma subtypes, suc...